Developing Novel Small Molecule Inhibitors of Serum & Glucocorticoid Regulated Kinase 1 (SGK1) for the Treatment of Fibrotic Diseases
Time: 3:00 pm
day: Day Two
Details:
- SGK1 is involved in the integration of pro-fibrotic signalling through the TGFb, PI3K, and MAPK pathways
- Inhibiting SGK1 decreases expression of several fibrotic markers in vitro and in vivo
- Leveraging how SGK1 inhibition offers a novel approach to address several pro-fibrotic pathways simultaneously
